Osteopontin (OPN) is a multifunctional glycoprotein integral to immune regulation, inflammation, and tissue remodeling, with significant roles in kidney and lung physiology. Initially associated with bone metabolism, OPN has emerged as a key mediator in pathological conditions like acute kidney injury (AKI) and chronic kidney disease (CKD). In kidneys, OPN modulates inflammation, immune cell migration, and fibrosis, with levels rising in response to kidney damage. This association makes OPN a potential biomarker for early detection and monitoring of CKD progression. In AKI, while OPN is linked to injury severity, its exact role is unclear, as evidence shows both protective and harmful effects in ischemia-reperfusion injury. Beyond renal pathology, OPN contributes to kidney-lung crosstalk, where kidney-derived OPN exacerbates lung inflammation and damage. Studies indicate that OPN interacts with lung receptors to induce acute lung injury (ALI), often complicating kidney disease. Preclinical studies suggest therapeutic potential in inhibiting OPN to reduce inflammation and fibrosis in both renal and pulmonary tissues. However, given OPN’s dual nature—protective yet pro-inflammatory—more research is necessary to establish effective interventions targeting OPN in kidney and respiratory diseases.